- First stated window
- “3Q26”SEC Form 8-K, Exhibit 99.1, filed
- Disclosure date
- SEC Form 8-K, Exhibit 99.1 · SEC original
Timeline
How wording is compared
Equivalent half-year, quarter, and year notations are compared together while original wording stays visible. Qualifiers such as early, mid, late, and end remain distinct. A slash and or are compared together for two complete timing alternatives with explicit years. Each source is compared with the preceding checked date. Different wording in documents from the same day is shown separately, without assigning an order within that day. No comparison is made against a preceding date with different timing expressions. Status is set by founder review of the original filings.
| Document | Date | Event retained | Exact company wording | Review | Source |
|---|---|---|---|---|---|
| SEC Form 8-K, Exhibit 99.1 | Initial entry within checked sources: “3Q26” | In January 2026, Viking announced completion of enrollment in the maintenance dosing study. The company expects to report the results of the study in 3Q26. | Checked by founder | SEC original | |
| SEC Form 8-K, Exhibit 99.1 | Statement retained: “3Q26” | In January 2026, Viking announced completion of enrollment in the maintenance dosing study. The company expects to report the results of the study in 3Q26. | Checked by founder | SEC original | |
| SEC Form 8-K, Exhibit 99.1 | Statement retained: “3Q26” | VK2735 Maintenance Dosing Data Expected 3Q26 | Checked by founder | SEC original | |
| SEC Form 8-K, Exhibit 99.1 | Disclosure | Viking Therapeutics, Inc. (“Viking”) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced positive top-line results from the company’s maintenance study of VK2735, the company’s dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. | Checked by founder | SEC original | |
| SEC Form 8-K (Cover filing) | Disclosure | On September 22, 2026, Viking Therapeutics, Inc. issued a press release announcing top-line results from its maintenance study of GLP-1/GIP agonist VK2735. A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference. | Checked by founder | SEC original |
Sources
- SEC Form 8-K, Exhibit 99.1 — filed 2026-02-11
- SEC Form 8-K, Exhibit 99.1 — filed 2026-04-29
- SEC Form 8-K, Exhibit 99.1 — filed 2026-07-29
- SEC Form 8-K, Exhibit 99.1 — filed 2026-09-22
- SEC Form 8-K (Cover filing) — filed 2026-09-22
- Company release — 2026-10-06
- Scope: SEC 8-K, Exhibit 99.1 — 2026-02-11 · “monthly subcutaneous dosing, daily oral dosing, and weekly oral dosing”
- Scope: SEC 8-K, Exhibit 99.1 — 2026-09-22 · “The company plans to explore oral maintenance dosing regimens in an upcoming part 2 to the current study.”
- Scope: Company press release — 2026-10-06 · “We look forward to reporting the results from Part 2 of this study in 2027.”
- Scope: SEC Form 10-Q — 2026-04-30
Last checked: . Compared by hand with the original filings by Jiwoo Seong (Woo).
Corrections
No corrections yet (as of ).
A correction is added here with its date, what changed, why, and the evidence. The earlier version is not deleted. Report an error: hello@orionbiotechai.com. If you want your name shown with the correction, include it; otherwise no name is shown.